the presentation is based on OECD guideline of chemical test on acute eye irritation guideline 403, it also give knowledge about why the guideline was updated and analgesic and anesthetic uses on the albino rabbit eye so to overcome the animal distress, and pain. the presentation explain the full guideline in detail

1. ACUTE EYE IRRITATION
OECD GUIDELINE 405
BY: PRIYA SHUKLA
SSR COLLEGE OF PHARMACY
DEPARTMENT PHARMACOLOGY

2. INTRODUCTION
• Acute Eye Irritation/Corrosion Guideline was
adopted in 1981 and updated in 1987, 2002,
and 2012.
• The latest article was updated on 9 october
2017.

3. • In previous reviews of this Test Guideline,
special attention was given to possible
improvements through the evaluation of all
existing information on the test substance in
order to avoid unnecessary testing in
laboratory animals and thereby address
animal welfare concerns.

4. • Testing in animals should only be conducted if
determined to be necessary after
consideration of available alternative
methods, and use of those determined tobe
appropriate.
• The latest update mainly focused on the use
of analgesics and anesthetics without
impacting the basic concept and structure of
the Test Guideline.

5. • The review concluded that the use of topical
anesthetics and systemic analgesics could
avoid most or all pain and distress without
affecting the outcome of the test, and
recommended that these substances should
always be used.

6. • Topical anesthetics, systemic analgesics, and
humane endpointsshould be routinely used
during acute eye irritation and corrosion in
vivotesting.Exceptions to their use should be
justified.
• The refinements described in this proposal will
substantially reduceor avoid animal pain and
distress in most testing situations

7. • Balanced preemptive pain management should
include
• (i) routine pretreatment with a topical anesthetic
(e.g., proparacaine or tetracaine) and a systemic
analgesic (e.g. buprenorphine),
• (ii)routine post-treatment schedule of systemic
analgesia (e.g., buprenorphine and meloxicam),
• (iii) scheduled observation, monitoring, and
recording of animals for clinical signs of pain
and/or distress, and
• (iv) scheduled observation, monitoring, and
recording of the nature, severity, and progression
of all eye injuries.

8. INITIAL CONSIDERATIONS
• For certain substances, such an analysis may
indicate the need for in vivo studies of the ocular
corrosion/irritation potential of the substance.
• In all such cases, before considering the use of
the in vivo eye test, preferably a study of the in
vitroand/or in vivo skin corrosion effects of the
substance should be conducted first and
evaluated in accordance with the sequential
testing strategy in Test Guideline 404

9. PRINCIPLE OF THE IN VIVO TEST
• Following pretreatment with a systemic
analgesic and induction of appropriate topical
anesthesia, the substance to be tested is
applied in a single dose to one of the eyes of
the experimental animal; the untreated eye
serves as the control.
• The degree of eye irritation/corrosion is
evaluated by scoring lesions of conjunctiva,
cornea, and iris, at specific intervals.

10. • Other effects in the eye and adverse systemic
effects are also described to provide a
complete evaluation of the effects. The
duration of the study should be sufficient to
evaluate the reversibility or irreversibility of
the effects.

11. PREPARATIONS FOR THE IN VIVO TEST
• 1. Selection of species :-
• The albino rabbit is the preferable laboratory
animal and healthy young adult animals are
used. A rationale for using other strains or
species should be provided.

12. 2. Preparation of animals
• Both eyes of each experimental animal
provisionally selected for testing should be
examined within 24 hours before testing
starts. Animals showing eye irritation, ocular
defects, or pre-existing corneal injury should
not be used.

13. 3. Housing and feeding conditions
• Animals should be individually housed.
• The temperature of the experimental animal
room should be 20°C (± 3°C) for rabbits.
• Although the relative humidity should be at
least 30% and preferably not exceed 70%,
other than during room cleaning, the aim
should be 50-60%.

14. • Lighting should be artificial, the sequence
being 12 hours light, 12 hours dark.
• Excessive light intensity should be avoided.

15. TEST PROCEDURE
Use of topical anesthetics and systemic
analgesics
• The following procedures are recommended
to avoid or minimize pain and distress in
ocular safety testing procedures.
1. Sixty minutes prior to test substance
application (TSA), buprenorphine 0.01 mg/kg
is administered by subcutaneous injection (SC)
to provide a therapeutic level of systemic
analgesia.

16. 2. Buprenorphine and other similar opiod
analgesics administered systemically are not
known or expected to alter ocular responses
3. Five minutes prior to TSA, one or two drops of
a topical ocular anesthetic (e.g. 0.5%
proparacaine hydrochloride or 0.5% tetracaine
hydrochloride) are applied to each eye.

17. 4. In order to avoid possible interference with
the study, a topical anesthetic that does not
contain preservatives is recommended.
5. The eye of each animal that is not treated
with a test article, but which is treated with
topical anesthetics, serves as a control.
6. If the test substance is anticipated to cause
significant pain and distress, it should not
normally be tested in vivo.

18. 7.However, in case of doubt or where testing is
necessary, consideration should be given to
additional applications of the topical
anesthetic at 5-minute intervals prior to TSA.
8.Users should be aware that multiple
applications of topical anesthetics could
potentially cause a slight increase in the
severity and/or time required for chemically-
induced lesions to clear.

19. 9. Eight hours after TSA, buprenorphine 0.01
mg/kg SC and meloxicam 0.5 mg/kg SC are
administered to provide a continued
therapeutic level of systemic analgesia.
10. While there are no data to suggest that
meloxicam has anti-inflammatory effects on
the eye when administered SC once daily,
meloxicam should not be administered until at
least 8 hours after TSA in order to avoid any
possible interference with the study

20. 11. After the initial 8-hour post-TSA treatment,
buprenorphine 0.01 mg/kg SC should be
administered every 12 hours, in conjunction
with meloxicam 0.5 mg/kg SC every 24 hours,
until the ocular lesions resolve and no clinical
signs of pain and distress are present.

21. 12. Sustained-release preparations of analgesics
are available that could be considered to
decrease the frequency of analgesic dosing.
13. “Rescue” analgesia should be given
immediately after TSA if pre-emptive
analgesia and topical anesthesia are
inadequate.

22. 14. If an animal shows signs of pain and distress
during the study, a “rescue” dose of
buprenorphine 0.03 mg/kg SC would be given
immediately and repeated as often as every 8
hours, if necessary, instead of 0.01 mg/kg SC
every 12 hours.
15. Meloxicam 0.5 mg/kg SC would be
administered every 24 hours in conjunction
with the “rescue” dose of buprenorphine, but
not until at least 8 hours post-TSA.

23. Application of the test substance
• The test substance should be placed in the
conjunctival sac of one eye of each animal
after gently pulling the lower lid away from
the eyeball.
• The lids are then gently held together for
about one second in order to prevent loss of
the material. The other eye, which remains
untreated, serves as a control.

24. Irrigation
1. The eyes of the test animals should not be
washed for at least 24 hours following instillation
of the test substance, except for solids and in
case of immediate corrosive or irritating effects.
At 24 hours a washout may be used if considered
appropriate.
2. Use of a satellite group of animals to investigate
the influence of washing is not recommended
unless it is scientifically justified.

25. • If a satellite group is needed, two rabbits
should be used. Conditions of washing should
be carefully documented, e.g., time of
washing; composition and temperature of
wash solution; duration, volume, and velocity
of application.

26. Dose level
1. Testing of liquids :-
For testing liquids, a dose of 0.1 mL is used.
Pump sprays should not be used for instilling
the substance directly into the eye.
The liquid spray should be expelled and
collected in a container prior to instilling 0.1
mL into the eye.

27. (2) Testing of solids
• When testing solids, pastes, and particulate
substances, the amount used should have a
volume of 0.1 mL or a weight of not more
than 100 mg.
• The test material should be ground to a fine
dust.

28. • The volume of solid material should be
measured after gently compacting it, e.g. by
tapping the measuring container.
• If the solid test substance has not been
removed from the eye of the test animal by
physiological mechanisms at the first
observation time point of 1 hour after
treatment, the eye may be rinsed with saline
or distilled water.

29. (3) Testing of aerosols
• It is recommended that all pump sprays and
aerosols be collected prior to instillation into
the eye.
• The one exception is for substances in
pressurised aerosol containers, which cannot
be collected due to vaporisation.

30. • In such cases, the eye should be held open,
and the test substance administered to the
eye in a simple burst of about one second,
from a distance of 10 cm directly in front of
the eye.
• This distance may vary depending on the
pressure of the spray and its contents. Care
should be taken not to damage the eye from
the pressure of the spray.

31. • In appropriate cases, there may be a need to
evaluate the potential for “mechanical”
damage to the eye from the force of the spray.
• An estimate of the dose from an aerosol can
be made by simulating the test as follows: the
substance is sprayed on to weighing paper
through an opening the size of a rabbit eye
placed directly before the paper.

32. • The weight increase of the paper is used to
approximate the amount sprayed into the eye.
• For volatile substances, the dose may be
estimated by weighing a receiving container
before and after removal of the test material.

33. Initial test (in vivo eye
irritation/corrosion test using one
animal)
• It is strongly recommended that the in vivo
test be performed initially using one animal
• Observations should allow for determination
of severity and reversibility before proceeding
to a confirmatory test in a second animal.
• If the results of this test indicate the
substance to be corrosive or a severe irritant
to the eye using the procedure described,
further testing for ocular irritancy should not
be performed.

34. Confirmatory test (in vivo eye irritation
test with additional animals)
• If a corrosive or severe irritant effect is not
observed in the initial test, the irritant or
negative response should be confirmed using
up to two additional animals.
• If an irritant effect is observed in the initial
test, it is recommended that the confirmatory
test be conducted in a sequential manner in
one animal at a time, rather than exposing the
two additional animals simultaneously.

35. • If the second animal reveals corrosive or
severe irritant effects, the test is not
continued. If results from the second animal
are sufficient to allow for a hazard
classification determination, then no further
testing should be conducted.

36. Observation period
• The duration of the observation period
should be sufficient to evaluate fully the
magnitude and reversibility of the effects
observed.
• However, the experiment should be
terminated at any time that the animal shows
signs of severe pain or distress

37. • To determine reversibility of effects, the
animals should be observed normally for 21
days post administration of the test substance.
If reversibility is seen before 21 days, the
experiment should be terminated at that time.

38. Clinical observations and grading of
eye reactions
• The eyes should be comprehensively
evaluated for the presence or absence of
ocular lesions one hour post-TSA, followed by
at least daily evaluations.
• Animals should be evaluated several times
daily for the first 3 days to ensure that
termination decisions are made in a timely
manner.

39. • Test animals should be routinely evaluated for
the entire duration of the study for clinical
signs of pain and/or distress (e.g. repeated
pawing or rubbing of the eye, excessive
blinking, excessive tearing) at least twice daily,
with a minimum of 6 hours between
observations, or more often if necessary.

40. • This is necessary to:
(i) adequately assess animals for evidence of
pain and distress in order to make informed
decisions on the need to increase the dosage
of analgesics and

41. (ii) assess animals for evidence of established
humane endpoints in order to make informed
decisions on whether it is appropriate to
humanely euthanize animals, and to ensure
that such decisions are made in a timely
manner.

42. • Digital photographs of observed lesions may
be collected for reference and to provide a
permanent record of the extent of ocular
damage.
• Animals should be kept on test no longer than
necessary once definitive information has
been obtained. Animals showing severe pain
or distress should be humanely killed without
delay, and the substance assessed accordingly.

43. • Animals with the following eye lesions post-
instillation should be humanely killed
• corneal perforation or significant corneal
ulceration including staphyloma; blood in the
anterior chamber of the eye; grade 4 corneal
opacity; absence of a light reflex which
persists for 72 hours; ulceration of the
conjunctival membrane; necrosis of the
conjunctivae or nictitating membrane; or
sloughing.

44. • This is because such lesions generally are not
reversible.
• Furthermore, it is recommended that the
following ocular lesions be used as humane
endpoints to terminate studies before the end
of the scheduled 21-day observation period.

45. • Once severe ocular effects have been
identified, an attending or qualified laboratory
animal veterinarian or personnel trained to
identify the clinical lesions should be
consulted for a clinical examination to
determine if the combination of these effects
warrants early study termination.

46. • The grades of ocular reaction (conjunctivae,
cornea and iris) should be obtained and
recorded at 1, 24, 48, and 72 hours following
test substance application.
• Animals that do not develop ocular lesions
may be terminated not earlier than 3 days
post instillation. Animals with ocular lesions
that are not severe should be observed until
the lesions clear, or for 21 days, at which time
the study is terminated.

47. • Observations should be performed and
recorded at a minimum of 1 hour, 24 hours, 48
hours, 72 hours, 7 days, 14 days, and 21 days
in order to determine the status of the lesions,
and their reversibility or irreversibility.
• More frequent observations should be
performed if necessary in order to determine
whether the test animal should be euthanized
out of humane considerations or removed
from the study due to negative results

48. • Examination of reactions can be facilitated by
use of a binocular loupe, hand slit-lamp,
biomicroscope, or other suitable device. After
recording the observations at 24 hours, the
eyes may be further examined with the aid of
fluorescein.

49. DATA AND REPORTING
1. Evaluation of results
• The ocular irritation scores should be
evaluated in conjunction with the nature and
severity of lesions, and their reversibility or
lack of reversibility.
• The individual scores do not represent an
absolute standard for the irritant properties of
a material, as other effects of the test material
are also evaluated.

50. • Instead, individual scores should be viewed as
reference values and are only meaningful
when supported by a full description and
evaluation of all observations.

51. Test report
• The test report should include the following
information:
1. description of relevant data available from
prior testing
2. data derived in each step of testing strategy
3. description of in vitro tests performed,
including details of procedures, results
obtained with test/reference substances

52. 4. description of in vivo dermal irritation /
corrosion study performed, including results
obtained
5. weight-of-the-evidence analysis for
performing in vivo study

53. Test substance:
1. identification data (e.g. chemical name and if
available CAS number, purity, known
impurities, source, lot number)
2. physical nature and physicochemical
properties (e.g. pH, volatility, solubility,
stability, reactivity with water)

54. 3. in case of a mixture, components should be
identified including identification data of the
constituent substances (e.g. chemical names
and if available CAS numbers) and their
concentration
4. dose applied

55. Vehicle
1. identification, concentration (where
appropriate), volume used
2. justification for choice of vehicle.

56. Test animals:
1. species/strain used, rationale for using
animals other than albino rabbit
2. age of each animal at start of study
3. number of animals of each sex in test and
control groups (if required)
4. individual animal weights at start and
conclusion of test
5. source, housing conditions, diet

57. Anaesthetics and analgesics
1. doses and times when topical anaesthetics
and systemic analgesics were administered
2. if local anaesthetic is used, identification,
purity, type, and potential interaction with
test substance.

58. Results:
1. description of method used to score irritation
at each observation time (e.g., hand slitlamp,
biomicroscope, fluorescein)
2. tabulation of irritant/corrosive response data
for each animal at each observation time up
to removal of each animal from the test

59. 3. narrative description of the degree and
nature of irritation or corrosion observed
4. description of any other lesions observed in
the eye (e.g., vascularization, pannus
formation, adhesions, staining)
5. description of non-ocular local and systemic
adverse effects, record of clinical signs of pain
and distress, digital photographs, and
histopathological findings, if any.

60. Interpretation of the results
• Extrapolation of the results of eye irritation
studies in laboratory animals to humans is
valid only to a limited degree. In many cases
the albino rabbit is more sensitive than
humans to ocular irritants or corrosives.
• Care should be taken in the interpretation of
data to exclude irritation resulting from
secondary infection.

61. GRADING OF OCULAR LESIONS
1. Cornea
No ulceration or opacity 0
Scattered or diffuse areas of opacity (other than slight dulling of normal
lustre); details of iris clearly visible
1
Easily discernible translucent area; details of iris slightly obscured 2
Easily discernible translucent area; details of iris slightly obscured 3
Opaque cornea; iris not discernible through the opacity 4
*The area of corneal opacity should be noted

62. 2. Iris
Normal 0
Markedly deepened rugae, congestion, swelling, moderate
circumcorneal hyperaemia; or injection; iris reactive to light (a sluggish
reaction is considered to be an effect
1
Hemorrhage, gross destruction, or no reaction to light 2

63. 3. Conjunctivae
Normal 0
Some blood vessels hyperaemic (injected) 1
Diffuse,crimson colour; individual vessels not easily discernible 2
Diffuse beefy red 3

64. 4. Chemosis (Swelling)
Normal 0
Some swelling above normal 1
Obvious swelling, with partial eversion of lids 2
Swelling, with lids about half closed 3
Swelling, with lids more than half closed 4